Bexacat in Cats

Bexacat is the brand name for bexagliflozin, an FDA-approved prescription medication used to improve glycemic control in certain cats with diabetes mellitus. It was approved in the United States in December 2022 as the first oral diabetes medication approved for cats. For some pet parents, that once-daily tablet can feel more manageable than insulin injections, but it is not the right fit for every diabetic cat.

The key point is patient selection. Bexacat is labeled for otherwise healthy cats with diabetes that have not previously been treated with insulin and that weigh at least 3 kg, or about 6.6 pounds. Cats that are insulin-dependent, have been treated with insulin before, or have important concurrent illness may face a higher risk of serious complications on this medication. Because of that, your vet will usually recommend bloodwork, urinalysis, and a careful review of your cat’s appetite, hydration, body weight, and overall health before starting it.

Bexacat can improve common diabetes signs such as increased thirst, increased urination, and increased appetite in many newly diagnosed cats. In FDA field studies, more than 80% of treated cats met study success criteria by day 56, with improvement in blood glucose measures and clinical signs. That said, the drug carries a boxed warning because severe adverse reactions, including diabetic ketoacidosis and euglycemic diabetic ketoacidosis, can occur.

For pet parents, the takeaway is balance. Bexacat offers a real oral treatment option, but it requires close screening and follow-up. If your cat is a candidate, your vet may discuss it alongside insulin-based care and diet changes so you can choose the approach that best fits your cat’s medical needs and your household routine.

Bexacat works in the kidneys, not by replacing insulin. Bexagliflozin blocks the sodium-glucose cotransporter 2, or SGLT2, in the proximal renal tubules. Normally, that transporter helps the body reabsorb filtered glucose back into the bloodstream. When it is blocked, more glucose leaves the body in the urine, which lowers blood glucose levels.

That mechanism is important because it explains both the benefit and the risk. In the right cat, Bexacat can reduce hyperglycemia quickly and improve signs of diabetes without injections. In FDA studies and veterinary references, cats treated with bexagliflozin showed decreases in blood glucose and fructosamine, along with improvement in polyuria, polydipsia, and polyphagia.

But Bexacat does not provide insulin. A cat still needs enough natural insulin production to use this medication safely. That is why it is intended only for selected newly diagnosed cats that are likely to be non-insulin-dependent. If a cat truly needs insulin, using an SGLT2 inhibitor alone can increase the risk of diabetic ketoacidosis, including cases where blood glucose is not dramatically elevated.

Because the drug increases urinary glucose loss, your vet may also talk with you about hydration, urine changes, and the need for regular monitoring. The goal is not only lower glucose numbers, but safer day-to-day diabetes control with careful follow-up.

See your vet immediately if your cat on Bexacat develops poor appetite, stops eating, becomes lethargic, vomits, has diarrhea, seems weak, has trouble walking, looks dehydrated, or starts losing weight. These signs can be early warnings of serious complications, including diabetic ketoacidosis or euglycemic diabetic ketoacidosis. The FDA client sheet and prescribing information advise stopping Bexacat and contacting your vet right away if these changes appear.

Commonly reported side effects include vomiting, diarrhea or loose stool, reduced appetite, lethargy, dehydration, and weight loss. In the FDA approval summary, other commonly noted abnormalities included elevated blood urea nitrogen, increased urine specific gravity related to glucosuria or dehydration, elevated feline pancreas-specific lipase, and ketones in the urine. Some cats may also develop or reveal problems such as pancreatitis or urinary tract issues during treatment.

The most serious concern is ketoacidosis, especially in cats that are not good candidates for the drug. This risk is one reason Bexacat has a boxed warning and should not be used in cats that have previously received insulin or are likely insulin-dependent. Serious adverse reactions, including death, were seen during development studies, which led to stricter screening recommendations before starting treatment.

Pet parents should not wait for dramatic symptoms. Even subtle changes like hiding more, grooming less, or skipping meals matter. Your vet may recommend regular rechecks with bloodwork, urine testing, ketone assessment, pancreatic markers, liver values, lipids, and body weight so problems can be caught early.

Bexacat is supplied as a 15 mg flavored tablet and is given by mouth once daily. The labeled dose is one 15 mg tablet per cat every 24 hours for cats weighing at least 3 kg, or 6.6 pounds. The dose is not adjusted based on body weight, blood glucose level, or response. It can be given with or without food and should be given at about the same time each day.

If you miss a dose, the FDA client sheet says to give it as soon as you remember on the same day, then continue on the regular schedule. If more than one tablet is accidentally given in the same day, contact your vet if you notice side effects. If no side effects are seen, the label advises continuing the regular schedule rather than doubling or skipping future doses.

Before starting Bexacat, your vet will usually confirm that your cat is an appropriate candidate. That often includes a physical exam, blood and urine testing, and screening for dehydration, pancreatitis, liver disease, kidney disease, ketones, and other concerns. Cats should also have a consistently good appetite leading up to treatment, because reduced appetite at baseline raises concern for complications.

Monitoring does not stop once the prescription starts. Your vet may recommend scheduled rechecks to assess clinical signs, hydration, body weight, blood glucose trends, fructosamine, ketones, and other lab values. If glycemic control remains poor after several weeks, your vet may discuss changing to insulin or another treatment plan.

Published veterinary interaction data for Bexacat are still limited compared with older feline medications, so your vet should review every prescription, supplement, and over-the-counter product your cat receives. The FDA client sheet specifically tells pet parents to inform their vet about all medications and any planned procedures involving anesthesia, such as surgery or dentistry. That matters because illness, fasting, dehydration, and stress around procedures may affect how safely a diabetic cat can stay on therapy.

The biggest practical concern is not a classic drug-drug interaction but a disease-and-treatment mismatch. Bexacat should not be used in cats currently receiving insulin, previously treated with insulin, or cats with conditions such as diabetic ketoacidosis, pancreatitis, kidney disease, liver disease, dehydration, lethargy, or poor appetite. Combining the wrong patient profile with this medication can sharply increase the risk of serious adverse events.

Your vet may also be cautious with medications or situations that can affect hydration, kidney values, appetite, or pancreatic health. For example, if a cat develops vomiting, diarrhea, reduced food intake, or needs anesthesia, your vet may reassess whether Bexacat should be paused or discontinued. That decision depends on the whole clinical picture, not one rule for every cat.

Because Bexacat causes glucose to spill into the urine, urine test interpretation can also change during treatment. Glucosuria is expected, so your vet will rely on a broader monitoring plan rather than urine glucose alone. Always check before starting new medications, changing diet, or scheduling elective procedures for a cat taking Bexacat.